NO136496B - - Google Patents
Download PDFInfo
- Publication number
- NO136496B NO136496B NO1289/69A NO128969A NO136496B NO 136496 B NO136496 B NO 136496B NO 1289/69 A NO1289/69 A NO 1289/69A NO 128969 A NO128969 A NO 128969A NO 136496 B NO136496 B NO 136496B
- Authority
- NO
- Norway
- Prior art keywords
- helveticoside
- group
- carbon atoms
- alkyl
- general formula
- Prior art date
Links
- QBILRDAMJUPXCX-AGAUEGNUSA-N Helveticoside Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 QBILRDAMJUPXCX-AGAUEGNUSA-N 0.000 claims description 25
- HKNQDCBTAOHPIM-UHFFFAOYSA-N Helveticosid Natural products CC1OCC(CC(O)C1O)OC2CCC3(C=O)C4CCC5(C)C(CCC5(O)C4CCC3(O)C2)C6=CC(=O)OC6 HKNQDCBTAOHPIM-UHFFFAOYSA-N 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 20
- DHKHKXVYLBGOIT-UHFFFAOYSA-N acetaldehyde Diethyl Acetal Natural products CCOC(C)OCC DHKHKXVYLBGOIT-UHFFFAOYSA-N 0.000 claims description 14
- 125000004432 carbon atom Chemical group C* 0.000 claims description 14
- 150000008143 steroidal glycosides Chemical class 0.000 claims description 14
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical class OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 10
- 125000000217 alkyl group Chemical group 0.000 claims description 10
- -1 methylenedioxy group Chemical group 0.000 claims description 10
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 7
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 7
- 238000002360 preparation method Methods 0.000 claims description 6
- 229910052799 carbon Inorganic materials 0.000 claims description 5
- 125000003342 alkenyl group Chemical group 0.000 claims description 4
- 239000003638 chemical reducing agent Substances 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 2
- CBOIHMRHGLHBPB-UHFFFAOYSA-N hydroxymethyl Chemical group O[CH2] CBOIHMRHGLHBPB-UHFFFAOYSA-N 0.000 claims description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 22
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
- 238000006243 chemical reaction Methods 0.000 description 18
- 150000001241 acetals Chemical class 0.000 description 15
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 14
- 239000000243 solution Substances 0.000 description 14
- 239000002904 solvent Substances 0.000 description 14
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 10
- 150000001299 aldehydes Chemical class 0.000 description 9
- 150000002576 ketones Chemical class 0.000 description 9
- 238000002844 melting Methods 0.000 description 8
- 230000008018 melting Effects 0.000 description 8
- 239000011541 reaction mixture Substances 0.000 description 8
- 150000001768 cations Chemical class 0.000 description 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 7
- 239000003208 petroleum Substances 0.000 description 7
- 230000035484 reaction time Effects 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 6
- HUMNYLRZRPPJDN-UHFFFAOYSA-N benzaldehyde Chemical compound O=CC1=CC=CC=C1 HUMNYLRZRPPJDN-UHFFFAOYSA-N 0.000 description 6
- 238000003776 cleavage reaction Methods 0.000 description 6
- 230000007017 scission Effects 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 239000012279 sodium borohydride Substances 0.000 description 6
- 229910000033 sodium borohydride Inorganic materials 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 6
- PVAIXHBTRMCOBL-OMFYFAIKSA-N (3s,5s,10s,13r,14s,17r)-3-[[(3ar,6r)-2,4-dimethyl-2-phenyl-4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-6-yl]oxy]-5,14-dihydroxy-13-methyl-17-(5-oxo-2h-furan-3-yl)-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthrene-10-carbaldehyde Chemical compound C([C@@H](OC([C@H]1O2)C)O[C@@H]3C[C@@]4(O)CCC5[C@@]6(O)CC[C@@H]([C@@]6(C)CCC5[C@@]4(C=O)CC3)C=3COC(=O)C=3)C1OC2(C)C1=CC=CC=C1 PVAIXHBTRMCOBL-OMFYFAIKSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 125000003172 aldehyde group Chemical group 0.000 description 5
- 229940097217 cardiac glycoside Drugs 0.000 description 5
- 239000002368 cardiac glycoside Substances 0.000 description 5
- 238000009833 condensation Methods 0.000 description 5
- 230000005494 condensation Effects 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 239000000203 mixture Substances 0.000 description 5
- 229930002534 steroid glycoside Natural products 0.000 description 5
- ZNDMLUUNNNHNKC-UHFFFAOYSA-N G-strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)CO)C3C1(O)CCC2C1=CC(=O)OC1 ZNDMLUUNNNHNKC-UHFFFAOYSA-N 0.000 description 4
- KISYRRMFQYIIFQ-PQLBFUHRSA-N Helveticosol Chemical compound C1[C@H](O)[C@H](O)[C@@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CCC3[C@@]4(O)CCC(C=5COC(=O)C=5)[C@@]4(C)CCC3[C@@]2(CO)CC1 KISYRRMFQYIIFQ-PQLBFUHRSA-N 0.000 description 4
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 4
- ODJLBQGVINUMMR-UHFFFAOYSA-N Strophanthidin Natural products CC12CCC(C3(CCC(O)CC3(O)CC3)C=O)C3C1(O)CCC2C1=CC(=O)OC1 ODJLBQGVINUMMR-UHFFFAOYSA-N 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 239000008346 aqueous phase Substances 0.000 description 4
- 239000002026 chloroform extract Substances 0.000 description 4
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 238000002329 infrared spectrum Methods 0.000 description 4
- 238000001990 intravenous administration Methods 0.000 description 4
- 230000000717 retained effect Effects 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- ODJLBQGVINUMMR-HZXDTFASSA-N strophanthidin Chemical compound C1([C@H]2CC[C@]3(O)[C@H]4[C@@H]([C@]5(CC[C@H](O)C[C@@]5(O)CC4)C=O)CC[C@@]32C)=CC(=O)OC1 ODJLBQGVINUMMR-HZXDTFASSA-N 0.000 description 4
- 238000004809 thin layer chromatography Methods 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 241000282326 Felis catus Species 0.000 description 3
- 229930183217 Genin Natural products 0.000 description 3
- ARUVKPQLZAKDPS-UHFFFAOYSA-L copper(II) sulfate Chemical compound [Cu+2].[O-][S+2]([O-])([O-])[O-] ARUVKPQLZAKDPS-UHFFFAOYSA-L 0.000 description 3
- 238000004821 distillation Methods 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- QNGNSVIICDLXHT-UHFFFAOYSA-N para-ethylbenzaldehyde Natural products CCC1=CC=C(C=O)C=C1 QNGNSVIICDLXHT-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 239000011592 zinc chloride Substances 0.000 description 3
- 235000005074 zinc chloride Nutrition 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- XQCGNURMLWFQJR-ZNDDOCHDSA-N Cymarin Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 XQCGNURMLWFQJR-ZNDDOCHDSA-N 0.000 description 2
- XQCGNURMLWFQJR-UESCRGIISA-N Cymarin Natural products O=C[C@@]12[C@@](O)(C[C@@H](O[C@H]3O[C@@H](C)[C@@H](O)[C@@H](OC)C3)CC1)CC[C@H]1[C@]3(O)[C@@](C)([C@H](C4=CC(=O)OC4)CC3)CC[C@H]21 XQCGNURMLWFQJR-UESCRGIISA-N 0.000 description 2
- KISYRRMFQYIIFQ-UHFFFAOYSA-N Helveticosol Natural products C1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(CO)CC1 KISYRRMFQYIIFQ-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 238000006359 acetalization reaction Methods 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 229960003083 cymarin Drugs 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 150000002338 glycosides Chemical class 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 2
- 238000005907 ketalization reaction Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000006386 neutralization reaction Methods 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- LPMXVESGRSUGHW-HBYQJFLCSA-N ouabain Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)C[C@@H](O)[C@@H]3[C@@]2(CO)[C@H](O)C1 LPMXVESGRSUGHW-HBYQJFLCSA-N 0.000 description 2
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 2
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- WPKQVDYSPWCVGM-UHFFFAOYSA-N (3beta,5beta)-3-[(2,6-dideoxy-3-O-methyl-beta-D-ribo-hexopyranosyl)oxy]-5,14,19-trihydroxycard-20(22)-enolide Natural products O1C(C)C(O)C(OC)CC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(CO)CC1 WPKQVDYSPWCVGM-UHFFFAOYSA-N 0.000 description 1
- SQEBMLCQNJOCBG-HVHJFMEUSA-N (5s)-3-(hydroxymethyl)-5-methoxy-4-methyl-5-[(e)-2-phenylethenyl]furan-2-one Chemical group C=1C=CC=CC=1/C=C/[C@]1(OC)OC(=O)C(CO)=C1C SQEBMLCQNJOCBG-HVHJFMEUSA-N 0.000 description 1
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- MWUDABUKTZAZCX-UHFFFAOYSA-N 1,1-diethoxycyclohexane Chemical compound CCOC1(OCC)CCCCC1 MWUDABUKTZAZCX-UHFFFAOYSA-N 0.000 description 1
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 1
- WPKQVDYSPWCVGM-ZNDDOCHDSA-N 3-[(3S,5S,8R,9S,10R,13R,14S,17R)-5,14-dihydroxy-3-[(2R,4S,5R,6R)-5-hydroxy-4-methoxy-6-methyloxan-2-yl]oxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-17-yl]-2H-furan-5-one Chemical compound O1[C@H](C)[C@@H](O)[C@@H](OC)C[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(CO)CC1 WPKQVDYSPWCVGM-ZNDDOCHDSA-N 0.000 description 1
- QNBADHCGFQKPKR-OMFYFAIKSA-N 3-[(3s,5s,10r,13r,14s,17r)-3-[[(3ar,6r)-2,4-dimethyl-2-phenyl-4,6,7,7a-tetrahydro-3ah-[1,3]dioxolo[4,5-c]pyran-6-yl]oxy]-5,14-dihydroxy-10-(hydroxymethyl)-13-methyl-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound C([C@@H](OC([C@H]1O2)C)O[C@@H]3C[C@@]4(O)CCC5[C@@]6(O)CC[C@@H]([C@@]6(C)CCC5[C@@]4(CO)CC3)C=3COC(=O)C=3)C1OC2(C)C1=CC=CC=C1 QNBADHCGFQKPKR-OMFYFAIKSA-N 0.000 description 1
- UQEKVLJMBGSQGS-MIXAURORSA-N 3-[(3s,5s,8r,9s,10r,13r,14s,17r)-5,14-dihydroxy-10-(hydroxymethyl)-13-methyl-3-[(2s,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-2,3,4,6,7,8,9,11,12,15,16,17-dodecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2h-furan-5-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(CO)CC1 UQEKVLJMBGSQGS-MIXAURORSA-N 0.000 description 1
- LPMXVESGRSUGHW-UHFFFAOYSA-N Acolongiflorosid K Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CC(O)C3C2(CO)C(O)C1 LPMXVESGRSUGHW-UHFFFAOYSA-N 0.000 description 1
- OPHYOSQDKQYDCM-UHFFFAOYSA-N Convallatoxin Natural products CC1OC(OC2CCC3(C=O)C4CCC5(C)C(CCC5(O)C4CCC3(O)C2)C6=CCC(=O)O6)C(O)C(O)C1O OPHYOSQDKQYDCM-UHFFFAOYSA-N 0.000 description 1
- UQEKVLJMBGSQGS-UHFFFAOYSA-N Desglucocheirotoxol Natural products OC1C(O)C(O)C(C)OC1OC1CC2(O)CCC3C4(O)CCC(C=5COC(=O)C=5)C4(C)CCC3C2(CO)CC1 UQEKVLJMBGSQGS-UHFFFAOYSA-N 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- FHIREUBIEIPPMC-UHFFFAOYSA-N K-Strophanthin-beta Natural products O1C(C)C(OC2C(C(O)C(O)C(CO)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 FHIREUBIEIPPMC-UHFFFAOYSA-N 0.000 description 1
- 239000002841 Lewis acid Substances 0.000 description 1
- RLAHWVDQYNDAGG-UHFFFAOYSA-N Methanetriol Chemical class OC(O)O RLAHWVDQYNDAGG-UHFFFAOYSA-N 0.000 description 1
- 238000000862 absorption spectrum Methods 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000010933 acylation Effects 0.000 description 1
- 238000005917 acylation reaction Methods 0.000 description 1
- 150000001338 aliphatic hydrocarbons Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 125000000649 benzylidene group Chemical group [H]C(=[*])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 150000001728 carbonyl compounds Chemical class 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 229940030602 cardiac therapy drug Drugs 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000001609 comparable effect Effects 0.000 description 1
- HULMNSIAKWANQO-JQKSAQOKSA-N convallatoxin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1O[C@@H]1C[C@@]2(O)CC[C@H]3[C@@]4(O)CC[C@H](C=5COC(=O)C=5)[C@@]4(C)CC[C@@H]3[C@@]2(C=O)CC1 HULMNSIAKWANQO-JQKSAQOKSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- MAQMEXSLUSZDQM-UHFFFAOYSA-N diethoxymethylbenzene Chemical compound CCOC(OCC)C1=CC=CC=C1 MAQMEXSLUSZDQM-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 239000003974 emollient agent Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 150000005826 halohydrocarbons Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000003301 hydrolyzing effect Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 229910052500 inorganic mineral Chemical class 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 1
- GILGYKHFZXQALF-UHFFFAOYSA-N k-Strophantylside Natural products O1C(C)C(OC2C(C(O)C(O)C(COC3C(C(O)C(O)C(CO)O3)O)O2)O)C(OC)CC1OC(CC1(O)CCC2C3(O)CC4)CCC1(C=O)C2CCC3(C)C4C1=CC(=O)OC1 GILGYKHFZXQALF-UHFFFAOYSA-N 0.000 description 1
- 125000000686 lactone group Chemical group 0.000 description 1
- 150000002596 lactones Chemical group 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 150000007517 lewis acids Chemical class 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 239000011707 mineral Chemical class 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 229960003343 ouabain Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000003884 phenylalkyl group Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- CHKVPAROMQMJNQ-UHFFFAOYSA-M potassium bisulfate Chemical compound [K+].OS([O-])(=O)=O CHKVPAROMQMJNQ-UHFFFAOYSA-M 0.000 description 1
- 239000001120 potassium sulphate Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 150000003431 steroids Chemical group 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000005809 transesterification reaction Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000007306 turnover Effects 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
- C07J19/005—Glycosides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J75/00—Processes for the preparation of steroids in general
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Steroid Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE19681768054 DE1768054A1 (de) | 1968-03-27 | 1968-03-27 | Herzglykosidderivate des Strophanthidintyps,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten |
| DE19681768142 DE1768142A1 (de) | 1968-04-04 | 1968-04-04 | Herzglykosidderivate des Strophantidintyps,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten |
| DE19681768140 DE1768140A1 (de) | 1968-04-04 | 1968-04-04 | Herzglykosidderivate des Strophanthidintyps,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten |
| DE19681768143 DE1768143A1 (de) | 1968-04-04 | 1968-04-04 | Herzglykosidderivate des Strophanthidintyps,Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung von Arzneipraeparaten |
| DE19691912518 DE1912518A1 (de) | 1969-03-12 | 1969-03-12 | Herzglykosidderivate des Strophanthidintyps,Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneipraeparate |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO136496B true NO136496B (cg-RX-API-DMAC7.html) | 1977-06-06 |
| NO136496C NO136496C (no) | 1977-09-21 |
Family
ID=27509961
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO1289/69A NO136496C (no) | 1968-03-27 | 1969-03-27 | Analogifremgangsm}te til fremstilling av terapeutisk aktive hjerteglykosidderivater |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US3951946A (cg-RX-API-DMAC7.html) |
| JP (2) | JPS4815941B1 (cg-RX-API-DMAC7.html) |
| BE (1) | BE730549A (cg-RX-API-DMAC7.html) |
| CH (1) | CH511223A (cg-RX-API-DMAC7.html) |
| DK (1) | DK118398B (cg-RX-API-DMAC7.html) |
| FI (1) | FI45555C (cg-RX-API-DMAC7.html) |
| FR (1) | FR2004858A1 (cg-RX-API-DMAC7.html) |
| GB (1) | GB1268221A (cg-RX-API-DMAC7.html) |
| IL (1) | IL31916A (cg-RX-API-DMAC7.html) |
| NO (1) | NO136496C (cg-RX-API-DMAC7.html) |
| SE (1) | SE370233B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2438128A1 (de) * | 1974-08-08 | 1976-02-19 | Boehringer Mannheim Gmbh | Verwendung von cyclischen helveticosidacetalen und ketalen zur behandlung von durchblutungsstoerungen |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL127424C (cg-RX-API-DMAC7.html) * | 1965-12-17 | |||
| DE1568216A1 (de) * | 1966-12-15 | 1970-03-19 | Boehringer Mannheim Gmbh | Verfahren zur Herstellung cyclischer AEther von Cardenolid-Digitoxosiden |
-
1969
- 1969-03-26 SE SE6904255A patent/SE370233B/xx unknown
- 1969-03-27 IL IL6931916A patent/IL31916A/xx unknown
- 1969-03-27 DK DK171469AA patent/DK118398B/da unknown
- 1969-03-27 JP JP44023497A patent/JPS4815941B1/ja active Pending
- 1969-03-27 GB GB06078/69A patent/GB1268221A/en not_active Expired
- 1969-03-27 FI FI690891A patent/FI45555C/fi active
- 1969-03-27 FR FR6909060A patent/FR2004858A1/fr not_active Withdrawn
- 1969-03-27 NO NO1289/69A patent/NO136496C/no unknown
- 1969-03-27 BE BE730549D patent/BE730549A/xx unknown
- 1969-03-27 CH CH474569A patent/CH511223A/de not_active IP Right Cessation
- 1969-03-27 JP JP2710569A patent/JPS532867B1/ja active Pending
-
1971
- 1971-08-10 US US05/170,635 patent/US3951946A/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| IL31916A (en) | 1974-06-30 |
| JPS532867B1 (cg-RX-API-DMAC7.html) | 1978-02-01 |
| IL31916A0 (en) | 1969-05-28 |
| CH511223A (de) | 1971-08-15 |
| FI45555B (cg-RX-API-DMAC7.html) | 1972-04-04 |
| DK118398B (da) | 1970-08-17 |
| US3951946A (en) | 1976-04-20 |
| GB1268221A (en) | 1972-03-22 |
| FR2004858A1 (cg-RX-API-DMAC7.html) | 1969-12-05 |
| BE730549A (cg-RX-API-DMAC7.html) | 1969-09-01 |
| FI45555C (fi) | 1972-07-10 |
| NO136496C (no) | 1977-09-21 |
| JPS4815941B1 (cg-RX-API-DMAC7.html) | 1973-05-18 |
| SE370233B (cg-RX-API-DMAC7.html) | 1974-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Mereyala et al. | A highly diastereoselective, practical synthesis of allyl, propargyl 2, 3, 4, 6-tetra-O-acetyl-β-d-gluco, β-d-galactopyranosides and allyl, propargyl heptaacetyl-β-d-lactosides | |
| US3524844A (en) | Epipodophyllotoxin glucoside derivatives | |
| SU902666A3 (ru) | Способ получени плевромутилиновых гликозидных производных | |
| EP0505572A1 (en) | Iridoide derivative and its use as medicine | |
| US4885280A (en) | Novel 14-amino steroids | |
| CH621803A5 (cg-RX-API-DMAC7.html) | ||
| JP5566392B2 (ja) | トリテルペノイド２−デオキシグリコシド、その調製方法、および医薬としてのその使用 | |
| CN109212044B (zh) | 一种奥贝胆酸有关物质的检测方法 | |
| CN114426538B (zh) | 一种小檗碱卡格列净衍生物及其制备方法和应用 | |
| WO1983001065A1 (fr) | Nouvelles saponines steroides, leur procede d'extraction, et procede de preparation de 16-dehydropregnenolone a partir de ces nouvelles saponines | |
| SU797583A3 (ru) | Способ получени антрациклин-глико-зидОВ | |
| CN101781352A (zh) | 20-o-糖基及其原人参二醇类化合物及其制备方法 | |
| KR900006236B1 (ko) | 3'-데메톡시에피포도필로톡신 배당체의 유도체 | |
| JPS63141992A (ja) | 新規なアンスラサイクリン誘導体およびその製造法 | |
| US3852265A (en) | 2{40 ,3{40 -o-lower alkylidene or cyclohexylidene periplorhamnoside compounds | |
| SATO et al. | Chemistry of the Spiroaminoketal Side Chain of Solasodine and Tomatidine. VI. 1 The Beckmann Rearrangement of the Oximino Derivatives | |
| US3812154A (en) | Dioxatricyclodecanes | |
| JPH0121146B2 (cg-RX-API-DMAC7.html) | ||
| KR920007273B1 (ko) | 프로토카테큐알데히드류의 당유도체 | |
| Goto et al. | Synthesis of conjugated cholesterol and cholestanols | |
| Kamano et al. | Steroids and related natural products. 85. Bufadienolides. 26. Direct conversion of 14-dehydrobufalin to bufalin | |
| Černý et al. | Preparation of 3-deoxy-3-fluoro-D-mannose and corresponding hexitol | |
| US4436735A (en) | Ketals of 3'"-dehydrocardenolide tridigitoxosides | |
| US3975373A (en) | Cardioglycoside derivatives of the strophanthidin type, a process for their manufacture and medicinal preparations containing these compounds | |
| JPS634557B2 (cg-RX-API-DMAC7.html) |